Description
BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.
Product information
Molecular Weight: 571.67
Formula: C29H25N5O4S2
Chemical Name: 2-(((R)-1-acryloylpyrrolidin-3-yl)carbamoyl)-5-(2-methyl-4-phenoxyphenyl)-4-oxo-4, 5-dihydro-3H-1-thia-3, 5, 8-triazaacenaphthylene 5-sulfide
Smiles: CC1=CC(=CC=C1[N+]1([S-])C2C=CN=C3SC(=C(NC1=O)C=23)C(=O)N[C@H]1CN(CC1)C(=O)C=C)OC1C=CC=CC=1
InChiKey: KXDSUZISVIOTQW-NISQWKGESA-N
InChi: InChI=1S/C29H25N5O4S2/c1-3-23(35)33-14-12-18(16-33)31-27(36)26-25-24-22(11-13-30-28(24)40-26)34(39,29(37)32-25)21-10-9-20(15-17(21)2)38-19-7-5-4-6-8-19/h3-11,13,15,18H,1,12,14,16H2,2H3,(H,31,36)(H,32,37)/t18-,34?/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
BTK inhibitor 18 (Compound 27) irreversibly inhibits BTK by targeting a noncatalytic cysteine residue (Cys481) for covalent bond formation. BTK inhibitor 18 (Compound 27) inhibits anti-IgM-induced activation of B cells in human whole blood with an IC50 of 84 nM. BTK inhibitor 18 (Compound 27) also inhibits BMX, LCK, ErbB4, TEC, and TXK kinases with IC50 values of 129 nM, 130 nM, 377 nM, 409 nM, 1770 nM, respectively.
In Vivo:
BTK inhibitor 18 (Compound 27; 1-30 mg/kg; oral administration; once a day; for 7 days) treatment shows dose-dependent efficacy at reducing joint inflammation in a rat collagen-induced arthritis model. The IV and PO pharmacokinetics of BTK inhibitor 18 (Compound 27) are investigated in nonfasted rats (1 and 5 mg/kg IV and PO) and fasted dogs (0.5 and 2.5 mg/kg IV and PO). IV pharmacokinetics are characterized by moderate clearance in rat and low clearance in dog, a moderate volume of distribution, and a short plasma half-life across both species (T1/2 of 0.3 h and 1.9 h for rat and dog, respectively). The oral bioavailability is 30% and 68% in rat and dog, respectively.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.